When her dad was diagnosed with pancreatic cancer, PanCAN’s Alyssa Lile experienced firsthand the mission she joined PanCAN ...
PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit talks about her experiences and highlights from the 2026 PanCAN ...
In 2026, in partnership with our generous donors and supporters, 12 research grants have been awarded through two programs. Grantees were selected through a peer-review process. PanCAN has awarded ...
The U.S. Food and Drug Administration has granted approval for a new drug targeting the mutations that drive more than 90% of pancreatic cancer cases — a sweeping advance for a disease that has few ...
For decades, pancreatic cancer research was defined by what seemed to be impossible. Researchers couldn’t target the mutations in the RAS family of proteins that drive more than 90% of cases. Often ...
Editor’s Note: Chicago Advocacy Chair Joanne Zborowski spoke with PanCAN’s Paula Mukherjee about her personal connection to PanCAN’s mission and advice for others who have lost a loved one to ...
The Pancreatic Cancer Action Network (PanCAN), the leading organization dedicated to advancing progress against pancreatic cancer, released a statement today following the full data from Revolution ...
I can’t think of a more exciting and hopeful time for pancreatic cancer than now. We are finally beginning to reap the benefits of decades of research into this challenging cancer. Because KRAS ...
Editor’s note: The “Research Spotlight” series is written by Dr. Anna Berkenblit, PanCAN’s Chief Scientific and Medical Officer. Each month, Dr. Berkenblit shares her insights into the latest news and ...
The U.S. Food and Drug Administration (FDA) has approved a wearable medical device used in combination with a standard chemotherapy regimen for the treatment of adult patients with locally advanced ...
LOS ANGELES, Calif. – (January 13, 2026) – Pancreatic cancer remains the third-leading cause of cancer-related deaths in the United States, behind lung and colorectal cancers. According to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results